Examples of using Development study in English and their translations into Bulgarian
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Computer
A pre- and postnatal development study was performed in rats.
No effects on the embryo orfoetus were seen at any dose level of Ultibro Breezhaler during an embryo-foetal development study in rats.
An embryo-foetal development study was conducted in guinea pigs, with no reported signs of toxicity.
The findings are based on data retrieved from the Adolescent Brain Cognitive Development study, or ABCD, which followed 10,000 teens over a 10 year period.
An embryofoetal development study has been conducted in monkeys administered lenalidomide at doses from 0.5 and up to 4 mg/kg/day.
People also translate
There were no effects on foetal body weights ormalformations attributed to maternal administration of dimethyl fumarate during the embryo-foetal development study in rats.
Data from an embryo-fetal development study in the rat, showed no evidence of any additional effect from the combination.
A possible treatment-related foetal skeletal malformation of fused arches was noted at highest dose tested in the rabbit embryo-foetal development study, in the absence of maternal toxicity.
The embryofetal development study in rats does not indicate direct or indirect harmful effects with respect to reproductive toxicity.
A potentially treatmentrelated increased incidence of the skeletal variant bipartite vertebral centrum anda single foetus with anorchism was seen at the highest dose tested in the rat embryo-foetal development study.
The data available from a rat embrofetal development study, where animals were given sodium aminosalicylate(3.85 to 385 mg/kg) were limited.
The performance of Major infrastructure Projects is often reported on for the purpose of further development, as in the case of the Athens Metro project with its‘Metro Development Study' and 20-year business plan.
The data comes from the British National Child Development Study, which follows all children born in England, Scotland, and Wales during one week in 1958.
Pre-clinical studies included in vitro and in vivo safety pharmacology assessments,repeated-dose inhalation toxicity studies in rats and dogs and an inhalation embryo-foetal development study in rats.
The findings come from the British National Child Development Study that includes data on all children born in England, Scotland, and Wales during one week in 1958.
Dose-dependent skin alterations, starting at dose levels equivalent to those used in humans,were the major findings observed in toxicity studies with Cynomolgus monkeys(a chronic repeat-dose toxicity study and an embryo-foetal development study).
In an embryo-foetal development study in rats, rucaparib was associated with post-implantation loss at exposures of approximately 0.04 times the human AUC at the recommended dose.
On the basis of the results,the no observed adverse effect level(NOAEL) was estimated to be near 4 mg/kg/day in the embryo-foetal development study in rats(23 times the human clinical exposures in adults based on AUC).
In an embryo-foetal development study in which pregnant rats were administered vismodegib daily during organogenesis, vismodegib crossed the placenta and was severely toxic to the conceptus.
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, or toxicity to reproduction and development, with the exception of a rat embryofoetal development study(subcutaneous administration).
The study examined data from the British National Child Development Study, which includes information from all children born in England, Scotland and Wales during 1 week in 1958.
In an embryo-foetal development study in rats, ossification delays of metatarsal bones were observed at systemic exposures 73 times and 19 times higher than the clinical exposures at the 100 mg and 300 mg doses.
In an embryo-foetal development study in rats, increased post-implantation loss, malformations(absence of caudal vertebrae and in some cases also of sacral vertebrae), skeletal variations and lower foetal body weights were observed.
During an embryo-fetal development study where siltuximab was administered intravenously to pregnant cynomolgus monkeys(gestation day 20- 118) at doses of 9.2 and 46 mg/kg/week, no maternal or fetal toxicity was observed.
In the rabbit embryofoetal development study, following administration of Myozyme(10-40 mg/kg/day) with coadministration of diphenhydramine, a treatment-related increase in the incidence of abortions and early delivery was observed.
In the peri-post natal development study, high doses of histamine dihydrochloride caused maternal toxicity, and the offspring showed toxicity during lactation(fewer live pups at day 21 compared to lactation at day 4) but not after weaning.
A pre- and postnatal development study in the mouse showed statistically significant reduced pup survival and pup growth during the weaning period at dose levels 125- and 25-fold higher.
In an embryo-foetal development study in the rat, increased incidences of dilated ureters, malformed sternebrae, and unossified forepaw phalanges were noticed at exposures of about 12(valsartan) and 10(amlodipine) times the clinical doses of 160 mg valsartan and 10 mg amlodipine.
In an embryo-foetal development study in which pregnant rats were administered daily doses of brigatinib during organogenesis; dose-related skeletal anomalies were observed at doses as low as approximately 0.7-times the human exposure by AUC at the 180 mg once daily dose.
An embryofetal development study in pregnant rats did not indicate a teratogenic effect attributed to the co-administration of empagliflozin and metformin at exposures of approximately 14-times the clinical AUC exposure of empagliflozin associated with the highest dose, and 4-times the clinical AUC exposure of metformin associated with the 2000 mg dose.